An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
Price : $35 *
At a glance
- Drugs Mipsagargin (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Inspyr Therapeutics
- 22 Feb 2017 Status changed from recruiting to completed.
- 14 Apr 2016 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
- 04 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov record.